Published On: Wed, Oct 19th, 2016

Hologic, Inc. (NASDAQ:HOLX) Updated Analyst Coverage


A number of investment brokers have recently updated their price targets on shares of Hologic, Inc. (NASDAQ:HOLX).

Most recent broker ratings

10/13/2016 – Hologic, Inc. had its “buy” rating reiterated by analysts at Evercore ISI. They now have a USD 43 price target on the stock.

09/30/2016 – Hologic, Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 46 price target on the stock.

09/23/2016 – Hologic, Inc. was upgraded to “overweight” by analysts at Barclays. They now have a USD 44 price target on the stock.

08/01/2016 – Hologic, Inc. had its “sector perform” rating reiterated by analysts at RBC Capital. They now have a USD 39 price target on the stock.

07/28/2016 – Hologic, Inc. had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 43 price target on the stock.

07/25/2016 – Hologic, Inc. had its “neutral” rating reiterated by analysts at Piper Jaffray. They now have a USD 40 price target on the stock.

07/14/2016 – Hologic, Inc. had its “buy” rating reiterated by analysts at UBS. They now have a USD 45 price target on the stock.

06/21/2016 – Hologic, Inc. had its “buy” rating reiterated by analysts at Bank of America Merrill Lynch.

04/29/2016 – Hologic, Inc. had its “buy” rating reiterated by analysts at Goldman Sachs. They now have a USD 45 price target on the stock.

04/28/2016 – Hologic, Inc. was downgraded to “hold” by analysts at Needham & Company.

12/11/2015 – Hologic, Inc. was upgraded to “buy” by analysts at Stifel Nicolaus. They now have a USD 45 price target on the stock.

11/26/2015 – Hologic, Inc. was upgraded to “outperform” by analysts at JP Morgan.

11/05/2015 – Hologic, Inc. had its “buy” rating reiterated by analysts at BTIG Research. They now have a USD 43 price target on the stock.

11/05/2015 – Hologic, Inc. had its “buy” rating reiterated by analysts at Canaccord Genuity. They now have a USD 45 price target on the stock.

10/26/2015 – Gabelli began new coverage on Hologic, Inc. giving the company a “buy” rating. They now have a USD 43 price target on the stock.

The share price of Hologic, Inc. (NASDAQ:HOLX) was up +0.40% during the last day of trading, with a day high of 39.02. 980962 shares were traded during the last session.

The stock’s 50 day moving average is 38.49 and its 200 day moving average is 36.44. The stock’s market capitalization is 10.74B. Hologic, Inc. has a 52-week low of 31.84 and a 52-week high of 41.66.

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays. It offers viral load assays for the quantitation of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus-1 (HIV-1). The Breast Health products include breast imaging and related products and accessories, including digital mammography systems, computer-aided detection (CAD) and breast biopsy guidance systems. The GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers and mini C-arm imaging systems.